

This is a published notice on the Find a Tender service: <https://www.find-tender.service.gov.uk/Notice/016860-2022>

Award

SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)

Ministry of Defence

F15: Voluntary ex ante transparency notice

Notice identifier: 2022/S 000-016860

Procurement identifier (OCID): ocds-h6vhtk-034881

Published 20 June 2022, 4:30pm

Section I: Contracting authority/entity

I.1) Name and addresses

Ministry of Defence

Bristol

Email

Tamika.Kelly116@mod.gov.uk

Country

United Kingdom

NUTS code

UK - United Kingdom

Internet address(es)

Main address

<https://www.gov.uk/>

I.4) Type of the contracting authority

Ministry or any other national or federal authority

I.5) Main activity

Defence

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)

II.1.2) Main CPV code

- 33651520 - Immunoglobulins

II.1.3) Type of contract

Supplies

II.1.4) Short description

The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent Biosolutions Canada Inc for the supply of Heptavalent Botulism Antitoxin (HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20m. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £22,000,000

II.2) Description

II.2.3) Place of performance

NUTS codes

- CA - Canada

II.2.4) Description of the procurement

The Chemical, Biological, Radiological and Nuclear (CBRN) team, part of Defence Equipment and Support (DE&S) organisation within the UK Ministry of Defence (MOD), intends to place a contract with Emergent for the supply of Heptavalent Botulism Antitoxin

(HBAT) for a period of 10 years (5 + 5 Option Years) with an estimated value of £20M+. This is necessary to ensure maintenance of the capability with an acceptable stockholding level.

Due to the estimated contract value and on the basis that it is to be placed directly with Emergent Biosolutions Canada Inc, the contract will be a Qualifying Defence Contract (QDC) and shall comply with the Single Source Contract Regulations (SSCR) 2014. It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where “Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons”.

Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: Yes

Description of options

5 Optional Years

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

II.2.14) Additional information

Due to the limitations of the character limit at II 2.4) Description — it is not possible to enter the full details of the single source justification, for full details of the reasoning, please email Tamika.Kelly116@mod.gov.uk so that it can be forwarded to you.

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Negotiated procedure without publication of a contract notice

- No tenders or no suitable tenders/requests to participate in response to negotiated procedure with prior publication of a contract notice
- The products involved are manufactured purely for the purpose of research, experiment, study or development
- The works, supplies or services can be provided only by a particular economic operator for the following reason:
 - absence of competition for technical reasons

Explanation:

It is considered that this contract can be awarded using the negotiated procedure without prior publication of a contract notice, pursuant to Public Contracts Regulations 2015; where "Regulation 32 (2)(b)(ii) allows you to use the Negotiated procedure without Prior Publication when the exclusivity is due to technical reasons". Summary of the Summary of the Technical Reason: Emergent Biosolutions Canada Inc are currently the only licensed manufacturer for HBAT (BAT®) which provides antitoxin serotypes A-G for treatment of Botulism worldwide. This product is therefore the only product which provides the full capability to Defence.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: No

Section V. Award of contract/concession

Contract No

CBRN/00272

Title

SUPPLY OF BOTULISM ANTITOXIN HEPTEVALENT (HBAT)

A contract/lot is awarded: Yes

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract

7 June 2022

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

Emergent Biosolutions Canada Inc

Winnipeg

Country

Canada

NUTS code

- CA - Canada

The contractor/concessionaire is an SME

No

V.2.4) Information on value of contract/lot/concession (excluding VAT)

Total value of the contract/lot/concession: £22,000,000

V.2.5) Information about subcontracting

The contract/lot/concession is likely to be subcontracted

Section VI. Complementary information

VI.4) Procedures for review

VI.4.1) Review body

Ministry of Defence

Bristol

Country

United Kingdom